Psoriasis (acute flare)MANAGEMENT

DERMATOLOGY PRESENTATIONS · 12 SECTIONS

⚲

673 items

☷ Legend

⚲

Cardiovascular Presentations66▾

Respiratory Presentations47▾

Neurological Presentations77▾

Gastrointestinal Presentations63▾

Genitourinary and Reproductive Presentations44▾

Infectious Disease Presentations146▾

Trauma Presentations88▾

Toxicologic Presentations67▾

Psychiatric Presentations25▾

Musculoskeletal and Rheumatologic Presentations89▾

Dermatology Presentations21▾

Allergic contact dermatitis Bullous Pemphigoid Cutaneous Abscess Eczema Herpeticum Erysipelas Erythema multiforme Henoch-Schönlein purpura Herpes Zoster (Shingles)Herpetic Whitlow Paronychia Pediculosis (Lice)Pemphigus Vulgaris Pilonidal Abscess Pressure injury Psoriasis (acute flare)Psoriasis Flare Staphylococcal Scalded Skin Syndrome Stevens-Johnson Syndrome (SJS)Toxic Epidermal Necrolysis (TEN)Urticaria (acute)Warfarin-induced Skin Necrosis

Environmental and Exposure Presentations26▾

Hematologic and Oncologic Presentations30▾

Pediatric-Specific Presentations13▾

Endocrine and Metabolic Presentations42▾

ENT and Maxillofacial Presentations21▾

Ophthalmologic Presentations15▾

Obstetric Presentations17▾

Systemic and Miscellaneous Presentations15▾

01Approach to the Critical Patient/attcp73

Triage and immediate risks

›Immediate severity screen

›Airway compromise

›Oropharyngeal edema

›Stridor

›Shock physiology

›SBP < 90 mmHg

›Lactate elevation

›Systemic toxicity

›Temperature ≥ 38.0 C

›Rigors

›Extensive skin failure patterns

›Erythroderma with BSA > 90%

›Generalized pustular eruption

›SJS TENS concern

›Mucosal involvement

›Skin pain out of proportion

›Immediate actions if unstable

›Escalate to resuscitation bay for hypotension

›Large bore IV access

›Crystalloid bolus 20 ml/kg

›If temperature ≥ 38.0 C with hypotension, sepsis pathway

›Broad spectrum antibiotics per local protocol

›Blood cultures before antibiotics if feasible

›If SJS TENS concern, stop all non essential medications immediately

›Burn unit or ICU consultation

›Dermatology consultation

High risk phenotypes and triggers

›High risk flare identification

›Erythrodermic psoriasis

›Thermoregulatory failure risk

›Fluid and protein loss risk

›Generalized pustular psoriasis

›Sepsis mimic risk

›Electrolyte derangement risk

›Palmoplantar pustulosis with functional impairment

›Ambulation limitation

›Secondary infection risk

›Trigger review

›Systemic corticosteroid exposure

›Withdrawal rebound risk

›Pustular conversion risk

›Infection triggers

›Streptococcal pharyngitis

›Viral illness

›Medication triggers

›Lithium

›Antimalarials

›Interferon

›Beta blockers

›Lifestyle and mechanical triggers

›Recent skin trauma

›Sunburn

›Alcohol excess

›Smoking

›Coding anchors

›ICD-10 L40.0 psoriasis vulgaris

›ICD-10 L40.1 generalized pustular psoriasis

›ICD-10 L40.8 other psoriasis

›ICD-10 L40.9 psoriasis unspecified

›ICD-10 L40.5 psoriatic arthropathy

›SNOMED CT term psoriasis

›SNOMED CT term pustular psoriasis

›SNOMED CT term erythrodermic psoriasis

Initial monitoring and targets

›Monitoring bundle for severe flare

›Continuous pulse oximetry

›Target SpO2 ≥ 94%

›Cardiac monitoring if tachycardia

›Heart rate trend

›Temperature trend

›Hypothermia risk in erythroderma

›Strict intake output

›Urine output target ≥ 0.5 ml/kg/hour

›Weight trend if admitted

›Fluid balance marker

02History/hx71

Presentation and course

›Symptom pattern

›Onset timing

›Sudden onset within 72 hours

›Subacute onset over weeks

›Pruritus severity

›Sleep disruption

›Excoriation behavior

›Pain severity

›Skin pain

›Fissure pain

›Functional impact

›Work or school impairment

›Ambulation limitation

›Flare context

›Prior psoriasis diagnosis

›Chronic plaque history

›Prior pustular episodes

›New diagnosis consideration

›First episode

›Family history

›Systemic symptoms

›Fever

›Measured temperature at home

›Antipyretic use

›Malaise

›Reduced oral intake

›Dehydration symptoms

›Arthralgia

›Morning stiffness

›Back pain pattern

Exposures and comorbidities

›Medication and treatment history

›Recent systemic corticosteroids

›Indication

›Stop date

›Current topical regimen

›Potency class

›Application frequency

›Systemic psoriasis therapies

›Methotrexate use

›Cyclosporine use

›Acitretin use

›Biologic therapy use

›New medications within 8 weeks

›Antibiotics

›Antiepileptics

›Infection risk and recent infections

›Sore throat

›Household strep exposure

›Skin infection history

›Prior impetigo

›Prior cellulitis

›Comorbid disease screening

›Cardiometabolic disease

›Diabetes

›Hypertension

›Hyperlipidemia

›Liver disease risk

›Alcohol use pattern

›Viral hepatitis history

›Kidney disease history

›Baseline creatinine knowledge

›Mental health impact

›Anxiety

›Depression

›Special situations

›Pregnancy possibility

›Last menstrual period timing

›Contraception use

›Immunosuppression

›Transplant history

›HIV risk

03Physical Exam/exam65

Skin and mucosa

›Morphology and distribution

›Plaques

›Well demarcated erythematous plaques

›Silvery scale

›Guttate pattern

›Drop like papules

›Trunk predominant

›Pustular lesions

›Sterile appearing pustules

›Coalescent lakes of pus

›Erythroderma pattern

›Diffuse erythema

›Generalized scaling

›Intertriginous involvement

›Inverse psoriasis pattern

›Maceration

›BSA estimation

›Palm method

›Patient palm equals 1% BSA

›Severe extent thresholds

›BSA ≥ 10% moderate to severe

›BSA > 90% erythroderma

›Mucosal findings

›Oral erosions

›SJS TENS concern marker

›Conjunctival injection

›Ocular involvement marker

›Secondary infection signs

›Honey colored crust

›Impetigo pattern

›Purulence

›Abscess pattern

›Warmth and tenderness

›Cellulitis pattern

Vitals and systemic assessment

›Hemodynamic status

›Tachycardia

›Dehydration marker

›Infection marker

›Hypotension

›Sepsis concern

›Volume depletion concern

›Hydration and perfusion

›Dry mucous membranes

›Volume depletion marker

›Capillary refill delay

›Hypoperfusion marker

›Temperature regulation

›Fever

›Infection or inflammatory flare

›Hypothermia

›Skin failure marker in erythroderma

Musculoskeletal and nails

›Joint findings

›Dactylitis

›Diffuse digit swelling

›Synovitis

›Warm swollen joint

›Axial tenderness

›Sacroiliac pain

›Nail findings

›Pitting

›Psoriatic nail dystrophy

›Onycholysis

›Distal nail separation

›Subungual hyperkeratosis

›Thickened nail bed

04Differential Diagnosis/ddx45

Life threatening and cannot miss

›Dangerous mimics

›Stevens Johnson syndrome toxic epidermal necrolysis

›Mucosal involvement

›Skin pain

›Recent high risk medication

›Sepsis with rash

›Hypotension

›Altered mental status

›Necrotizing soft tissue infection

›Severe focal pain

›Rapid progression

›Psoriasis emergencies

›Erythrodermic psoriasis

›BSA > 90%

›Thermoregulatory instability

›Generalized pustular psoriasis

›Fever with pustules

›Leukocytosis

Common mimics and overlaps

›Papulosquamous mimics

›Atopic dermatitis

›Flexural predominance

›Lichenification

›Contact dermatitis

›Clear exposure pattern

›Vesiculation

›Tinea corporis

›Annular plaques

›Central clearing

›Pityriasis rosea

›Herald patch

›Christmas tree distribution

›Seborrheic dermatitis

›Greasy scale

›Scalp and face predominance

›Pustular mimics

›Acute generalized exanthematous pustulosis

›Recent drug exposure

›Facial edema

›Impetigo

›Honey colored crust

›Erythroderma differentials

›Drug eruption

›New medication timing

›Cutaneous T cell lymphoma

›Chronic refractory course

05Laboratory Tests/lt44

Core labs for severe flare

›Severity and systemic inflammation set

›Complete blood count for leukocytosis

›Neutrophilia in pustular flare

›Eosinophilia in drug eruption

›Electrolytes for skin failure

›Sodium abnormality with dehydration

›Potassium abnormality with GI loss

›Creatinine for renal perfusion

›AKI risk in erythroderma

›Cyclosporine eligibility marker

›Liver enzymes for systemic therapy safety

›Methotrexate eligibility marker

›Acitretin eligibility marker

›CRP for inflammatory burden

›High value supports systemic flare

›Very high value supports infection differential

Infection evaluation when febrile

›Infection workup set

›Blood cultures for fever with systemic toxicity

›Two sets from separate sites

›Before antibiotics if feasible

›Lactate for shock assessment

›Rising trend marker

›Target downtrend with resuscitation

›Urinalysis when urinary symptoms

›Pyuria marker

›Bacteriuria marker

›Throat testing when guttate pattern with sore throat

›Rapid strep test

›Throat culture

Pre treatment screening for systemic escalation

›Systemic therapy screening set

›Pregnancy test for childbearing potential

›Required before retinoids

›Required before methotrexate

›Hepatitis B screening for biologic consideration

›HBsAg

›Anti HBc

›Hepatitis C screening for biologic consideration

›Anti HCV

›RNA if antibody positive

›HIV screening when risk factors

›Baseline immunosuppression marker

›TB screening for biologic consideration

›IGRA test

›Chest radiograph if positive

06Diagnostic Tests/dt48

Scoring Systems

›Psoriasis severity metrics

›BSA percentage

›Mild BSA < 3%

›Moderate BSA 3% to 10%

›Severe BSA > 10%

›PASI score

›Erythema component

›Induration component

›Scaling component

›PGA score

›Clear to severe scale

›Treatment response tracking

›DLQI score

›Quality of life impairment marker

›Systemic therapy justification support

MRI

›MRI indications

›Suspected psoriatic arthritis with axial symptoms

›Sacroiliitis evaluation

›Enthesitis evaluation

›Suspected osteomyelitis under chronic plaques

›Deep pain

›Ulcer over bony prominence

›MRI limitations

›Limited utility for cutaneous flare diagnosis

›Clinical diagnosis predominance

›Dermatology exam primacy

›CT indications

›Deep soft tissue infection concern under plaques

›Fluctuance with systemic signs

›Severe focal pain

›Alternate diagnosis evaluation when uncertain

›Abscess mapping

›Necrotizing infection adjunct

›CT limitations

›Not a routine psoriasis test

›Radiation exposure

›Limited cutaneous specificity

Ultrasound

›Point of care ultrasound uses

›Soft tissue infection evaluation

›Abscess vs cellulitis

›Guidance for drainage planning

›Musculoskeletal evaluation in psoriatic arthritis

›Effusion detection

›Enthesitis detection

›Ultrasound limitations

›Limited role in plaque diagnosis

›Clinical morphology predominance

›Dermoscopy or biopsy when unclear

07Disposition/dispo43

Admission and higher level of care

›Admit criteria

›Erythrodermic psoriasis

›BSA > 90%

›Temperature instability

›Generalized pustular psoriasis with systemic symptoms

›Fever

›Leukocytosis

›Hemodynamic instability

›Hypotension

›Persistent tachycardia with dehydration

›Significant dehydration

›Inability to maintain oral intake

›AKI

›Superimposed serious infection

›Cellulitis with systemic signs

›Bacteremia

›ICU or monitored bed triggers

›Shock physiology

›Vasopressor requirement

›Rising lactate

›Severe electrolyte derangement

›Sodium abnormality with symptoms

›Potassium abnormality with ECG changes

Discharge and follow up

›Discharge criteria

›Stable vitals

›Afebrile

›Normal blood pressure

›No SJS TENS features

›No mucosal lesions

›No skin pain out of proportion

›Limited extent flare

›BSA not in erythroderma range

›No generalized pustules

›Reliable follow up

›Dermatology appointment plan

›Primary care follow up plan

›Follow up timing

›Dermatology within 1 to 2 weeks for moderate flare

›Systemic therapy discussion

›Phototherapy consideration

›Dermatology within 24 to 72 hours for pustular flare

›Escalation to systemic rescue therapy

›Infection exclusion confirmation

08Treatment/t141

Supportive care and skin barrier

›Barrier restoration bundle

›Emollients

›Petrolatum based ointment

›Apply at least twice daily

›Apply after bathing

›Thick fragrance free cream

›Apply after hand washing

›Apply to fissures

›Bathing and scale softening

›Lukewarm short baths

›Avoid hot water

›Pat dry

›Occlusion options

›Plastic wrap short contact over thick plaques

›Avoid occlusion if infection concern

›Pruritus control

›Non sedating antihistamine

›Cetirizine 10 mg PO daily

›Loratadine 10 mg PO daily

›Sedating antihistamine at night when needed

›Hydroxyzine 10 mg to 25 mg PO at bedtime

›Drowsiness counseling

›Pain control bundle

›Acetaminophen

›15 mg/kg PO every 6 hours as needed

›Maximum 4000 mg per day adult

›NSAID when no contraindication

›Ibuprofen 10 mg/kg PO every 6 hours as needed

›Maximum 2400 mg per day adult

Topical anti inflammatory therapy

›Topical corticosteroids by site

›Trunk and extremities

›Clobetasol 0.05% ointment

›Thin layer once to twice daily

›Maximum continuous use 2 weeks

›Betamethasone dipropionate 0.05% ointment

›Thin layer once to twice daily

›Taper frequency when improved

›Face and intertriginous areas

›Hydrocortisone 1% to 2.5% cream

›Thin layer once to twice daily

›Short course 7 to 14 days

›Tacrolimus 0.03% ointment

›Thin layer twice daily

›Steroid sparing option

›Scalp

›Fluocinonide 0.05% solution

›Apply once to twice daily

›Avoid dripping into eyes

›Clobetasol 0.05% shampoo

›Contact time 15 minutes

›Use daily for up to 4 weeks

›Steroid adverse effect mitigation

›Skin atrophy risk

›Avoid high potency on face

›Avoid prolonged occlusion

›HPA axis suppression risk

›Avoid large area high potency long duration

›Pediatric higher risk

Non steroid topical adjuncts

›Vitamin D analogs

›Calcipotriol 0.005% cream

›Apply twice daily

›Avoid face and folds

›Calcipotriol betamethasone combination

›Apply once daily

›Adherence improvement option

›Keratolytics for scale

›Salicylic acid 3% to 6% preparations

›Apply to thick scale

›Avoid large area use in young children

›Urea 20% to 40% cream

›Apply to hyperkeratotic plaques

›Fissure softening

›Tar preparations

›Coal tar shampoo for scalp

›Adjunct for scale

›Odor counseling

Systemic rescue therapy for severe flare

›Systemic escalation principles

›Dermatology consultation for systemic initiation

›Same day for generalized pustular psoriasis

›Same day for erythrodermic psoriasis

›Avoid systemic corticosteroids as routine psoriasis flare therapy

›Rebound flare risk

›Pustular conversion risk

›Cyclosporine

›Dosing range

›2.5 mg/kg/day PO divided twice daily

›5 mg/kg/day PO divided twice daily

›Monitoring

›Creatinine baseline and repeat

›Blood pressure monitoring

›Contraindications

›Uncontrolled hypertension

›Significant renal dysfunction

›Methotrexate

›Dosing

›7.5 mg PO weekly

›25 mg PO weekly

›Folic acid supplementation

›1 mg PO daily

›5 mg PO weekly on non methotrexate day

›Monitoring

›CBC monitoring

›Liver enzymes monitoring

›Contraindications

›Pregnancy

›Significant liver disease

›Acitretin

›Dosing

›0.3 mg/kg/day PO

›0.5 mg/kg/day PO

›Contraindications

›Pregnancy

›Severe hypertriglyceridemia

›Monitoring

›Lipid panel monitoring

›Liver enzymes monitoring

›Biologic rapid control options for pustular crisis under specialist care

›Infliximab

›5 mg/kg IV once

›Repeat per induction schedule under specialist plan

›IL 36 receptor antagonist for generalized pustular psoriasis under specialist care

›Spesolimab 900 mg IV once

›Repeat dosing per protocol if persistent disease

Evidence and recommendation notes

›Recommendation strength mapping used in this reference

›Class I recommendation

›Benefits clearly outweigh risks

›Strong consensus among guideline bodies

›Class IIa recommendation

›Benefits likely outweigh risks

›Moderate quality evidence or consensus

›Class IIb recommendation

›Benefits possibly outweigh risks

›Limited evidence

›Topical corticosteroids for localized plaque flare

›Class I recommendation

›First line for most localized flares

›Rapid symptom control

›Systemic rescue therapy for erythrodermic or generalized pustular flare

›Class I recommendation

›Dermatology led systemic therapy

›Hospital level supportive care when unstable

09Special Populations/sp48

Pregnancy

›Pregnancy considerations

›Safer first line options

›Emollients

›Liberal use

›Fragrance free

›Low to medium potency topical corticosteroids

›Short courses

›Small area preference

›Narrowband UVB phototherapy

›Steroid sparing option

›Folate supplementation consideration

›Avoided therapies

›Methotrexate

›Teratogenicity

›Contraindicated

›Acitretin

›Teratogenicity

›Contraindicated

›Severe flare escalation under specialist care

›Cyclosporine consideration

›Maternal blood pressure monitoring

›Renal function monitoring

›TNF inhibitor continuation or initiation consideration

›Placental transfer counseling by trimester

›Neonatal live vaccine timing discussion

Geriatric

›Geriatric considerations

›Comorbidity burden

›Heart failure risk with severe erythroderma stress

›Diabetes impact on skin infection risk

›Medication safety

›Renal dosing awareness for cyclosporine

›Hepatic reserve awareness for methotrexate

›Skin fragility

›Steroid atrophy risk

›Tear risk with adhesives

Pediatrics

›Pediatric considerations

›Potency selection

›Low potency on face and folds

›Short duration high potency only with specialist input

›Systemic absorption risk

›Higher BSA to weight ratio

›Occlusion avoidance unless directed

›Guttate psoriasis association

›Recent streptococcal infection pattern

›Throat evaluation consideration

›Weight based dosing for systemic therapies

›Specialist led initiation

›Monitoring plan required

10Background/b38

Epidemiology

›Epidemiology overview

›Chronic immune mediated inflammatory skin disease

›Relapsing remitting course

›Multisystem comorbidity associations

›Common phenotypes

›Chronic plaque psoriasis

›Guttate psoriasis

›Pustular psoriasis

›Psoriatic arthritis association

›Joint disease screening importance

›Nail disease correlation

Pathophysiology

›Pathophysiology framework

›Immune axis

›IL 23 pathway activation

›Th17 cytokines

›Keratinocyte hyperproliferation

›Thickened stratum corneum

›Scale formation

›Koebner phenomenon

›Lesions at trauma sites

›Mechanical trigger relevance

Therapeutic Considerations

›Therapeutic goals

›Barrier restoration

›Reduce transepidermal water loss

›Reduce fissuring

›Inflammation suppression

›Topical anti inflammatory for localized disease

›Systemic therapy for severe disease

›Trigger modification

›Infection treatment

›Medication reconciliation

›Systemic corticosteroid caution rationale

›Rebound inflammation risk

›Flare after taper

›Pustular shift

›Alternative rapid control options

›Cyclosporine for crisis under specialist care

›Biologic rapid onset options under specialist care

11Patient Discharge Instructions/pdi35

copy discharge instructions

›Psoriasis flare care at home

›Moisturizer

›Thick fragrance free ointment or cream at least twice daily

›Apply right after bathing

›Topical medication use

›Apply exactly as prescribed

›Avoid high potency steroid on face or groin unless directed

›Bathing

›Lukewarm water

›Gentle unscented cleanser

›Triggers

›Avoid skin trauma and picking

›Avoid new non prescribed creams on plaques

›Follow up

›Dermatology appointment as arranged

›Primary care follow up for long term plan

›Return to ED now

›Fever

›Temperature ≥ 38.0 C

›Chills or feeling very unwell

›Rapidly spreading redness

›Whole body redness

›New widespread peeling

›Blisters or sores on lips or eyes

›Mouth sores

›Eye pain or redness

›Trouble breathing

›Wheeze

›Throat tightness

›Severe weakness or dizziness

›Fainting

›Signs of dehydration

›Increasing pain or pus

›Possible skin infection

›Red streaking

12References/r22

Clinical guidelines and evidence sources

›Guideline sources

›American Academy of Dermatology National Psoriasis Foundation guidelines for topical therapy

›Topical corticosteroids

›Vitamin D analogs

›American Academy of Dermatology National Psoriasis Foundation guidelines for systemic non biologic therapy

›Methotrexate

›Cyclosporine

›Acitretin

›American Academy of Dermatology National Psoriasis Foundation guidelines for biologic therapy

›TNF inhibitors

›IL 17 inhibitors

›IL 23 inhibitors

›British Association of Dermatologists psoriasis guidelines

›Severity assessment

›Treatment escalation

›Evidence grading notes

›ACEP Level A B C framework

›Not psoriasis specific

›Included for system wide consistency

›Class I IIa IIb framework

›Not a universal dermatology standard

›Used here to communicate recommendation strength

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.